Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763287 | 0.86 | CRHR1 (0.41) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL4763245 | 0.86 | CRHR1 (0.46) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL4762104 | 0.84 | CRHR1 (0.43) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL4793019 | 0.83 | CRHR1 (0.43) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL4763067 | 0.82 | CRHR1 (0.43) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL4762385 | 0.82 | CRHR1 (0.43) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL4767150 | 0.81 | CRHR1 (0.43) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL2193222 | 0.81 | CRHR1 (0.49) | CRHR1DRD2HTR1ACACNA2D1CACNA2D2 | |
| SCHEMBL4767336 | 0.81 | CRHR1 (0.42) | CRHR1DRD2HTR2AHTR7HTR6 | |
| SCHEMBL13986668 | 0.80 | CRHR1 (0.42) | CRHR1DRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | claimed |
| EP-1395591-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-04 | — | — | EP | claimed |
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1395591-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-04 | — | — | EP | disclosed |
| US-20050054661-A1 | Corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1395591-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002100863-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054661-A1 | Corticotropin releasing factor antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885DRD2 164/4885HTR2A 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.